Nicole Sweeny's most recent trade in KalVista Pharmaceuticals Inc was a trade of 5,000 Common Stock done . Disclosure was reported to the exchange on Aug. 22, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| KalVista Pharmaceuticals Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2025 | 5,000 | 33,771 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2025 | 5,000 | 55,000 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Nicole Sweeny | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 13.42 per share. | 22 Aug 2025 | 1,480 | 32,291 (0%) | 0% | 13.4 | 19,862 | Common Stock |
| KalVista Pharmaceuticals Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2025 | 6,250 | 30,635 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2025 | 6,250 | 87,500 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Nicole Sweeny | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 13.22 per share. | 21 Aug 2025 | 1,864 | 28,771 (0%) | 0% | 13.2 | 24,647 | Common Stock |
| Praxis Precision Medicines... | Nicole Sweeny | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.94 per share. | 12 Feb 2023 | 1,456 | 38,619 | - | 3.9 | 5,737 | Common Stock |
| Praxis Precision Medicines... | Nicole Sweeny | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Praxis Precision Medicines... | Nicole Sweeny | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 41,085 | 41,085 | - | - | Stock Option (Right to Buy) | |
| Praxis Precision Medicines... | Nicole Sweeny | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.52 per share. | 07 Jan 2023 | 2,079 | 40,075 | - | 2.5 | 5,239 | Common Stock |
| Praxis Precision Medicines... | Nicole Sweeny | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Praxis Precision Medicines... | Nicole Sweeny | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 8.80 per share. | 13 May 2022 | 2,587 | 42,154 | - | 8.8 | 22,760 | Common Stock |
| Praxis Precision Medicines... | Nicole Sweeny | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.85 per share. | 12 Feb 2022 | 1,233 | 39,567 | - | 12.8 | 15,844 | Common Stock |
| Praxis Precision Medicines... | Nicole Sweeny | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 84,000 | 84,000 | - | - | Stock Option (Right to Buy) | |
| Praxis Precision Medicines... | Nicole Sweeny | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 24,000 | 40,800 | - | 0 | Common Stock | |
| Praxis Precision Medicines... | Nicole Sweeny | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 58,880 | 58,880 | - | - | Stock Option (Right to Buy) | |
| Praxis Precision Medicines... | Nicole Sweeny | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 16,800 | 16,800 | - | 0 | Common Stock |